Skip to main content
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · AMLX ISIN · US0321085088 US Manufacturing
Filings indexed 383 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US AMLX

About Amylyx Pharmaceuticals, Inc.

https://www.amylyx.com/

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative diseases and other conditions with high unmet medical needs. The company's primary therapeutic candidate was AMX0035 for the treatment of amyotrophic lateral sclerosis (ALS). In April 2024, following the results of a Phase 3 clinical trial, Amylyx announced it would voluntarily withdraw the marketing authorizations for AMX0035 in the U.S. and Canada. The company is advancing a pipeline of other investigational therapies, utilizing a modality-agnostic approach to match treatments to diseases based on mechanistic rationale and rigorous scientific data.

Recent filings

Filing Released Lang Actions
10-Q - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-07 English
8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
Regulatory Filings
2026-05-07 English
ARS - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
Annual Report
2026-04-23 English
DEF 14A - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
Proxy Solicitation & Information Statement
2026-04-23 English
8-K - Amylyx Pharmaceuticals, Inc. (0001658551) (Filer)
Investor Presentation Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated March 24, 2026, by Amylyx Pharmaceuticals, Inc. The key content is an update to the corporate presentation for investors and analysts, reflecting clinical trial enrollment updates and other study data. The document explicitly states that the presentation is attached as Exhibit 99.1 and is being furnished, not filed, and is not subject to liabilities of a formal filing. The document is short (3924 characters) and primarily announces the furnishing of a corporate presentation rather than containing the presentation itself or detailed financial data. This matches the description of an Investor Presentation (IP) filing type, as it is a detailed presentation for investors focusing on financials, strategy, and market position. Therefore, the classification is Investor Presentation (IP) with high confidence.
2026-03-24 English
4 - AMYLYX PHARMACEUTICALS, INC. (0001658551) (Filer)
Director's Dealing
2026-03-04 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.